Outcome of the studies regarding breast cancer treatment and adverse effects.

Study design: CCT, clinical controlled trial; Cos, cohort study; CSS, cross sectional study; pts, patients; RCT, randomized controlled trial; SR, systematic review.Intervention: ALND, axillary lymph node dissection; art, article; CE, cyclophosphamide, epirubicin; CEF, cyclophosphamide, epirubicin and fluorouracil; CT, chemotherapy; FU, follow up; Gy, Grey; HT, hormonal therapy; IMB, internal mammarial boost; IM-MS, internal mammary and medial supraclavicular lymph node chain; IORT, intra operative radiotherapy; LRRT, locoregional radiotherapy corresponding to periclavicular, axillary level 3, and for right-side breast cancers, the internal mammary nodes; LN, lymph node; M, metastasis; N, nodal status; PAB, posterior axillary boost; RT, radiotherapy; SC, supra scapular; SNB, sentinel node biopsy; T, docetaxel; T, tumor; TAM, tamoxifen; vs., versus; wks, weeks; ZOL, Zoledronic Acid.Measurement instruments: BIS, bio impedance spectroscopy; BMI, body mass index; BSI, Brief Symptom Inventory; CPAQ, Chronic Pain Acceptance Questionnaire; CES-D, center for epidemiologic studies – depression scale; CTCAE, Common Terminology Criteria for Adverse Events ; DASH, disabilities of arm, shoulder and hand; EORTC-QLQ-C30-BR23, European organization for research and treatment of cancer – quality of life questionnaire- breast; FACT-G-B, functional assessment of cancer therapy – general – breast; FLIC, Functional living index – cancer; FQ, fatigue questionnaire; FPACQ, Flemish Physical Activity Computerized Questionnaire; GCQ, general coping questionnaire; HADS, hospital anxiety and depression scale; ICD, international classification of diseases; IOC, impact of cancer scale; KAPS, Kwan’s arm problem scale; LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; LBCQ, lymphedema breast cancer questionnaire; LEFT-BC, Lymphedema Evaluation Following Treatment for Breast Cancer; LENT-SOMA, late effects normal tissue – subjective objective management analytic; Li-Sat, life satisfaction; MASS, measure of arm symptoms survey; MET, metabolic equivalent ; MOS, medical outcomes study; MPQ, McGill pain questionnaire; MRC-scale, medical research council scale; MSPQ, Modified Somatic Perception Questionnaire; NPRS, numeric pain rating scale; PAISSR, Psychological Adjustment to Illness Scale-Self-Report; PAQ, physical activity questionnaire; PSI-B, Problem solving inventory-brief; ROM, range of motion; SF-36, short form-36; SPADI, shoulder pain and disability index; ULDQ, upper limb disability questionnaire; v, version; VAS, visual analogue scale; WHR, Waist-Hip ratio.Outcomes: ADL, activities in daily living; AWS, axillary web syndrome; CHF, cardiac heart failure; CTS, carpal tunnel syndrome; HR, Hazard Ratio; LE, lymphedema; LVEF, left ventricular ejection fraction; ns, non-significant; OR, odds ratio; MPS, myofascial pain syndrome; MSD, musculoskeletal disorders; PA, physical activity; PMPS, Post Mastectomy Pain Syndrome; RR, relative risk; sign, significant; *, data extracted from included studies.